Page last updated: 2024-08-26

yttrium radioisotopes and Central Nervous System Neoplasm

yttrium radioisotopes has been researched along with Central Nervous System Neoplasm in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hamm, B; Jahnke, K; Kiewe, P; Korfel, A; Maza, S; Munz, DL; Thiel, E	1
Doolittle, ND; Dósa, E; Kraemer, DF; Lewin, SJ; Muldoon, LL; Neuwelt, EA; Pagel, MA	1
Abrey, LE; Divgi, CR; Humm, J; Iwamoto, FM; Pandit-Taskar, N; Peak, S; Schwartz, J; Zelenetz, AD	1

Trials

2 trial(s) available for yttrium radioisotopes and Central Nervous System Neoplasm

Article	Year
First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma. Neuro-oncology, 2009, Volume: 11, Issue:4 Topics: Adult; Aged; Antibodies, Monoclonal; Central Nervous System Neoplasms; Female; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Radioimmunotherapy; Remission Induction; Survival Rate; Tissue Distribution; Yttrium Radioisotopes	2009
Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma. Cancer, 2007, Dec-01, Volume: 110, Issue:11 Topics: Aged; Central Nervous System Neoplasms; Disease-Free Survival; Female; Humans; Indium Radioisotopes; Male; Middle Aged; Radioimmunotherapy; Radiotherapy Dosage; Recurrence; Survival Rate; Yttrium Radioisotopes	2007

Article

Year

First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma.

Neuro-oncology, 2009, Volume: 11, Issue:4

Topics: Adult; Aged; Antibodies, Monoclonal; Central Nervous System Neoplasms; Female; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Radioimmunotherapy; Remission Induction; Survival Rate; Tissue Distribution; Yttrium Radioisotopes

2009

Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma.

Cancer, 2007, Dec-01, Volume: 110, Issue:11

Topics: Aged; Central Nervous System Neoplasms; Disease-Free Survival; Female; Humans; Indium Radioisotopes; Male; Middle Aged; Radioimmunotherapy; Radiotherapy Dosage; Recurrence; Survival Rate; Yttrium Radioisotopes

2007

Other Studies

1 other study(ies) available for yttrium radioisotopes and Central Nervous System Neoplasm

Article	Year
Imaging and therapy with rituximab anti-CD20 immunotherapy in an animal model of central nervous system lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Apr-15, Volume: 17, Issue:8 Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain; Cell Line, Tumor; Central Nervous System Neoplasms; Female; Humans; Lymphoma, B-Cell; Magnetic Resonance Imaging; Methotrexate; Random Allocation; Rats; Rats, Nude; Rituximab; Survival Analysis; Treatment Outcome; Xenograft Model Antitumor Assays; Yttrium Radioisotopes	2011

Article

Year

Imaging and therapy with rituximab anti-CD20 immunotherapy in an animal model of central nervous system lymphoma.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Apr-15, Volume: 17, Issue:8

Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain; Cell Line, Tumor; Central Nervous System Neoplasms; Female; Humans; Lymphoma, B-Cell; Magnetic Resonance Imaging; Methotrexate; Random Allocation; Rats; Rats, Nude; Rituximab; Survival Analysis; Treatment Outcome; Xenograft Model Antitumor Assays; Yttrium Radioisotopes

2011